Haemonetics Co. (NYSE:HAE) Shares Sold by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP decreased its position in Haemonetics Co. (NYSE:HAE) by 1.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 699,861 shares of the medical instruments supplier’s stock after selling 12,200 shares during the quarter. Westfield Capital Management Co. LP owned 1.38% of Haemonetics worth $59,733,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. TFO Wealth Partners LLC grew its position in shares of Haemonetics by 29,450.0% during the fourth quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier’s stock worth $51,000 after buying an additional 589 shares in the last quarter. Parkside Financial Bank & Trust grew its position in shares of Haemonetics by 17.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier’s stock worth $90,000 after buying an additional 156 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Haemonetics during the first quarter worth approximately $114,000. Central Pacific Bank Trust Division acquired a new stake in shares of Haemonetics during the first quarter worth approximately $139,000. Finally, LVZ Inc. grew its position in shares of Haemonetics by 9.4% during the fourth quarter. LVZ Inc. now owns 3,006 shares of the medical instruments supplier’s stock worth $257,000 after buying an additional 259 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Buying and Selling

In related news, EVP Anila Lingamneni sold 2,305 shares of Haemonetics stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $95.00, for a total value of $218,975.00. Following the transaction, the executive vice president now owns 12,295 shares of the company’s stock, valued at approximately $1,168,025. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Haemonetics news, EVP Anila Lingamneni sold 2,305 shares of the firm’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $95.00, for a total transaction of $218,975.00. Following the completion of the sale, the executive vice president now directly owns 12,295 shares in the company, valued at approximately $1,168,025. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Stewart W. Strong sold 686 shares of the firm’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $95.11, for a total value of $65,245.46. Following the sale, the insider now owns 18,196 shares of the company’s stock, valued at $1,730,621.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 29,516 shares of company stock valued at $2,638,056. 1.80% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on HAE. JMP Securities raised their price objective on Haemonetics from $115.00 to $125.00 and gave the stock a “market outperform” rating in a research note on Friday, May 10th. Needham & Company LLC upgraded Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 target price on the stock in a research note on Wednesday, June 12th. Finally, Barrington Research raised their target price on Haemonetics from $105.00 to $107.00 and gave the company an “outperform” rating in a research note on Friday, May 10th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $109.50.

Haemonetics Stock Performance

Shares of NYSE HAE traded up $2.14 during midday trading on Friday, reaching $88.73. 326,961 shares of the company traded hands, compared to its average volume of 569,885. Haemonetics Co. has a 52 week low of $70.74 and a 52 week high of $97.97. The stock has a 50-day moving average price of $87.58 and a 200 day moving average price of $83.65. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.56 and a quick ratio of 1.50. The company has a market cap of $4.52 billion, a price-to-earnings ratio of 38.75, a PEG ratio of 1.62 and a beta of 0.29.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.02. The firm had revenue of $343.00 million for the quarter, compared to analyst estimates of $329.53 million. Haemonetics had a return on equity of 22.25% and a net margin of 8.98%. Haemonetics’s revenue was up 12.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.77 earnings per share. Sell-side analysts anticipate that Haemonetics Co. will post 4.57 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.